Type 1 diabetes and (C-X-C motif) ligand (CXCL) 10 chemokine

Clinica Terapeutica

Volumn 165, Issue 2, 2014, Pages

  Corrado, A ^a   Ferrari, S M ^a   Ferri, C ^b   Ferrannini, E ^a   Antonelli, A ^a   Fallahi, P ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Autoimmunity; CXCL10; CXCR3; Diabetes; Type 1 diabetes

Indexed keywords

EID: 84899763519     PISSN: 00099074     EISSN: 19726007     Source Type: Journal    
DOI: 10.7471/CT.2014.1706     Document Type: Review

References (66)

1. Loetscher M, Gerber B, Loetscher P, et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996; 184:963-9
2. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukocyte Bio 1997; 61:246-57
3. Cole KE, Strick CA, Paradis TJ, et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998; 187:2009-21
4. Loetscher M, Loetscher P, Brass N, et al. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol 1998; 28:3696-705
5. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000; 52:145-76
6. Agostini C, Calabrese F, Rea F, et al. Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am J Pathol 2001; 158:1703-11
7. Melter M, Exeni A, Reinders ME, et al. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation 2001; 104:2558-64
8. Hancock WW, Wang L, Ye Q, et al. Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Curr Opin Immunol 2003; 15:479-86
9. Engel MA, Neurath MF. Anticancer properties of the IL-12 family focus on colorectal cancer. Curr Med Chem 2010; 17:3303-8
10. Antonelli A, Ferrari SM, Giuggioli D, et al. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev 2013 Nov 2 Autoimmun Rev. 2014; 13(3):272-80. doi: 10.1016/j.autrev.2013.10.010. Epub 2013 Nov 2
11. Antonelli A, Rotondi M, Fallahi P, et al. Increase of CXC chemokine CXCL10 and CC chemokine CCL2 serum levels in normal ageing. Cytokine 2006; 34:32-8
12. Antonelli A, Ferrari SM, Frascerra S, et al. Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10. Cytokine 2011; 55:288-93
13. Antonelli A, Fallahi P, Rotondi M, et al. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. Br J Surg 2006; 93:1226-31
14. Antonelli A, Rotondi M, Fallahi P, et al. Iodine-131 Given for Therapeutic Purposes Modulates Differently Interferon-{gamma}-Inducible {alpha}-Chemokine CXCL10 Serum Levels in Patients with Active Graves' Disease or Toxic Nodular Goiter. J Clin Endocrinol Metab 2007; 92:1485-90
15. Antonelli A, Ferrari SM, Fallahi P, et al. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2009; 94:1803-9
16. Lee EY, Lee ZH, Song YW. The interaction between CXCL10 and cytokines in chronic inflammatory arthritis. Autoimmun Rev 2013; 12:554-7
17. Lacotte S, Brun S, Muller S, et al. CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci 2009; 1173:310-7
18. Antonelli A, Ferri C, Fallahi P, et al. CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis--a longitudinal study. Rheumatology (Oxford) 2008; 47:45-9
19. Antonelli A, Ferri C, Fallahi P, et al. Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis. J Rheumatol 2008; 35:1809-11
20. Antonelli A, Delle Sedie A, Fallahi P, et al. High prevalence of thyroid autoimmunity and hypothyroidism in patients with psoriatic arthritis. J Rheumatol 2006; 33:2026-8
21. Antonelli A, Fallahi P, Delle Sedie A, et al. High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthtritis. Clin Exp Rheumatol 2009; 27:22-7
22. Antonelli A, Fallahi P, Delle Sedie A, et al. High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis. Autoimmunity 2008; 41:537-42
23. Su R, Nguyen ML, Agarwal MR, et al. Interferon-inducible chemokines reflect severity and progression in sarcoidosis. Respir Res 2013; 14:121
24. Antonelli A, Fazzi P, Fallahi P, et al. Prevalence of hypothyroidism and Graves disease in sarcoidosis. Chest 2006; 130:526-32
25. Antonelli A, Ferri C, Fallahi P, et al. Thyroid involvement in patients with overt HCV-related mixed cryoglobulinaemia. QJM 2004; 97:499-506
26. Antonelli A, Ferri C, Fallahi P, et al. High Values of CXCL10 Serum Levels in Mixed Cryoglobulinemia Associated With Hepatitis C Infection. Am J Gastroenterol 2008; 103:2488-94
27. Ferri C, Antonelli A, Mascia MT, et al. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig Liver Dis 2007; 39 Suppl 1:S13-21
28. Ferri C, Antonelli A, Mascia MT, et al. B-cells and mixed cryoglobulinemia. Autoimmun Rev 2007; 7:114-20
29. Herold KC, Vignali DA, Cooke A, et al. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol 2013; 13:243-56
30. Juvenile Diabetes Research Foundation, "Type 1 Diabetes Facts," 2012, http://www.jdrf.org/index.cfm?page_id=102585
31. Barbeau WE. What is the key environmental trigger in type 1 diabetes is it viruses, or wheat gluten, or both? Autoimmun Rev 2012; 12:295-9
32. Askenasy EM, Askenasy N. Is autoimmune diabetes caused by aberrant immune activity or defective suppression of physiological self-reactivity? Autoimmun Rev 2013; 12:633-7
33. Antonelli A, Tuomi T, Nannipieri M, et al. Autoimmunity to CD38 and GAD in Type I and Type II diabetes: CD38 and HLA genotypes and clinical phenotypes. Diabetologia 2002; 45:1298-306
34. Antonelli A, Baj G, Marchetti P, et al. Human anti-CD38 autoantibodies raise intracellular calcium and stimulate insulin release in human pancreatic islets. Diabetes 2001; 50:985-91
35. Zekzer D, Wong FS, Ayalon O, et al. GAD-reactive CD4+ Th1 cells induce diabetes in NOD/SCID mice. J Clin Invest 1998; 101:68-73
36. Amrani A, Verdaguer J, Thiessen S, et al. IL-1a, IL-1ß, and IFN-? mark ß cells for Fas-dependent destruction by diabetogenic CD4+ T lymphocytes. J Clin Invest 2000; 105:459-68
37. Lo J, Clare-Salzler MJ. Dendritic cell subsets and type I diabetes: focus upon DC-based therapy. Autoimmun Rev 2006; 5:419-23
38. Shimada A, Morimoto J, Kodama K, et al. Elevated serum IP-10 levels observed in type 1 diabetes. Diabetes Care 2001; 24:510-5
39. Nicoletti F, Conget I, Di Mauro M, et al. Serum concentrations of the interferon-gamma-inducible chemokine IP-10/ CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 2002; 45:1107-10
40. Nakagawa Y, Shimada A, Oikawa Y, et al. Two cases of "fulminant" type 1 diabetes suggesting involvement of autoimmunity. Ann N Y Acad Sci 2003; 1005:359-61
41. Gabbay MA, Sato MN, Duarte AJ, et al. Serum titres of antiglutamic acid decarboxylase-65 and anti-IA-2 autoantibodies are associated with different immunoregulatory milieu in newly diagnosed type 1 diabetes patients. Clin Exp Immunol 2012; 168:60-7
42. Rotondi M, Romagnani P, Brozzetti A, et al. to: Nicoletti F, Conget L, Di Mauro M et al. (2002) Serum concentrations of the interferon-alpha-inducible chemokine IP-10/CXCL10 are augmented in both newly-diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 2003; 46:1020-1 Diabetologia 45:1107-10
43. Hanifi-Moghaddam P, Kappler S, Seissler J, et al. Altered chemokine levels in individuals at risk of Type 1 diabetes mellitus. Diabet Med 2006; 23:156-63
44. Antonelli A, Fallahi P, Ferrari SM, et al. Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study. Diabet Med 2008; 25:1349-53
45. Shanmugam N, Ransohoff RM, Natarajan R. Interferongamma-inducible protein (IP)-10 mRNA stabilized by RNA-binding proteins in monocytes treated with S100b. J Biol Chem 2006; 281:31212-21
46. Rosa JS, Mitsuhashi M, Oliver SR, et al. Ex vivo TCRinduced leukocyte gene expression of inflammatory mediators is increased in type 1 diabetic patients but not in overweight children. Diabetes Metab Res Rev 2010; 26:33-9
47. Frigerio S, Junt T, Lu B, et al. Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Nat Med 2002; 8:1414-20
48. Roep BO, Kleijwegt FS, van Halteren AG, et al. Islet inflammation and CXCL10 in recent-onset type 1 diabetes. Clin Exp Immunol 2010; 159:338-43
49. Uno S, Imagawa A, Saisho K, et al. Expression of chemokines, CXC chemokine ligand 10 (CXCL10) and CXCR3 in the inflamed islets of patients with recent-onset autoimmune type 1 diabetes. Endocr J 2010; 57:991-6
50. Tozzoli R, Barzilai O, Ram M, et al. Infections and autoimmune thyroid diseases: parallel detection of antibodies against pathogens with proteomic technology. Autoimmun Rev 2008; 8:112-5
51. Antonelli A, Fallahi P, Nesti C, et al. Anti-CD38 autoimmunity in patients with chronic autoimmune thyroiditis or Graves' disease. Clin Exp Immunol 2001; 126:426-31
52. Burek CL, Rose NR. Autoimmune thyroiditis and ROS. Autoimmun Rev 2008; 7:530-7
53. Antonelli A, Rotondi M, Fallahi P, et al. High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism J Clin Endocrinol Metab 2004; 89:5496-9
54. Antonelli A, Fallahi P, Rotondi M, et al. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol 2006; 154:651-8
55. Kimura H, Kimura M, Rose NR, et al. Early chemokine expression induced by interferon-gamma in a murine model of Hashimoto's thyroiditis. Exp Mol Pathol 2004; 77:161-7
56. Fiore E, Rago T, Latrofa F, et al. Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr Relat Cancer 2011; 18:429-37
57. Antonelli A, Ferri C, Fallahi P, et al. Thyroid cancer in HCVrelated mixed cryoglobulinemia patients. Clin Exp Rheumatol 2002; 20:693-6
58. Antonelli A, Ferri C, Fallahi P, et al. Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study. Thyroid 2007; 17:447-51
59. Spinelli C, Bertocchini A, Antonelli A, et al. Surgical therapy of the thyroid papillary carcinoma in children: experience with 56 patients < or =16 years old. J Pediatr Surg 2004; 39:1500-5
60. Neri S, Boraschi P, Antonelli A, et al. Pulmonary function, smoking habits, and high resolution computed tomography (HRCT) early abnormalities of lung and pleural fibrosis in shipyard workers exposed to asbestos. Am J Ind Med 1996; 30:588-95
61. Antonelli A, Miccoli P, Derzhitski VE, et al. Epidemiologic and clinical evaluation of thyroid cancer in children from the Gomel region (Belarus). World J Surg 1996; 20:867-71
62. Antonelli A, Fallahi P, Ferrari SM, et al. Dedifferentiated thyroid cancer: A therapeutic challenge. Biomed Pharmacother 2008; 62:559-63
63. Melillo RM, Castellone MD, Guarino V, et al. The RET/PTCRAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005; 115:1068-81
64. Antonelli A, Ferrari SM, Fallahi P, et al. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferatoractivated receptor-gamma agonists. Endocr Relat Cancer 2009; 16:1299-311
65. Morimoto J, Yoneyama H, Shimada A, et al. CXC chemokine ligand 10 neutralization suppresses the occurrence of diabetes in nonobese diabetic mice through enhanced beta cell proliferation without affecting insulitis. J Immunol 2004; 173:7017-24
66. Shigihara T, Shimada A, Oikawa Y, et al. CXCL10 DNA vaccination prevents spontaneous diabetes through enhanced beta cell proliferation in NOD mice. J Immunol 2005; 175:8401-8